Skip to main content

EQRx, Inc. (Nasdaq: EQRX) a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced that data from its partner CStone Pharmaceuticals’ two pivotal Phase 3 studies of the anti-PD-L1 monoclonal antibody sugemalimab for the treatment of non-small cell lung cancer (NSCLC), GEMSTONE-301 and GEMSTONE-302, were published in The Lancet Oncology.

Read Article